Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomized, double-blind, placebo-controlled phase 3 trial
Burmester GR et al. Lancet 2018. doi: 10.1016/S0140-6736(18)31115-2
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.